PE61899A1 - Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico - Google Patents

Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico

Info

Publication number
PE61899A1
PE61899A1 PE1998000177A PE00017798A PE61899A1 PE 61899 A1 PE61899 A1 PE 61899A1 PE 1998000177 A PE1998000177 A PE 1998000177A PE 00017798 A PE00017798 A PE 00017798A PE 61899 A1 PE61899 A1 PE 61899A1
Authority
PE
Peru
Prior art keywords
composition
mixtures
conservative
ionic
prostaglandine
Prior art date
Application number
PE1998000177A
Other languages
English (en)
Spanish (es)
Inventor
Kenneth Warren Reed
Shau-Fong Yen
Mary Sou
Regina Flinn Peacock
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE61899(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE61899A1 publication Critical patent/PE61899A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE1998000177A 1997-03-17 1998-03-13 Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico PE61899A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17

Publications (1)

Publication Number Publication Date
PE61899A1 true PE61899A1 (es) 1999-06-30

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000177A PE61899A1 (es) 1997-03-17 1998-03-13 Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico

Country Status (32)

Country Link
EP (1) EP0969846B2 (enExample)
JP (2) JP4920124B2 (enExample)
KR (1) KR100555818B1 (enExample)
CN (1) CN1236775C (enExample)
AR (2) AR002194A1 (enExample)
AT (1) ATE257385T1 (enExample)
AU (1) AU738781B2 (enExample)
BR (2) BR9808016A (enExample)
CA (1) CA2280089C (enExample)
CL (1) CL2009001870A1 (enExample)
CO (1) CO4940427A1 (enExample)
CY (1) CY2526B1 (enExample)
CZ (1) CZ299833B6 (enExample)
DE (1) DE69820997T3 (enExample)
DK (1) DK0969846T4 (enExample)
EE (1) EE04091B1 (enExample)
ES (1) ES2214706T5 (enExample)
HU (1) HU228896B1 (enExample)
ID (1) ID22389A (enExample)
IL (1) IL131041A0 (enExample)
MY (1) MY122237A (enExample)
NO (1) NO327713B1 (enExample)
NZ (1) NZ337322A (enExample)
PE (1) PE61899A1 (enExample)
PL (1) PL197509B1 (enExample)
PT (1) PT969846E (enExample)
RU (1) RU2197970C2 (enExample)
SI (1) SI0969846T2 (enExample)
TW (1) TW527187B (enExample)
UA (1) UA63938C2 (enExample)
WO (1) WO1998041208A1 (enExample)
ZA (1) ZA982188B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
JP4000505B2 (ja) 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
CA2422031C (en) * 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
WO2002045748A1 (en) * 2000-12-05 2002-06-13 Sankyo Company, Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
CA2558135C (en) * 2004-03-18 2012-08-14 R-Tech Ueno, Ltd. Aqueous composition comprising thiazole derivative
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
DE202005005094U1 (de) * 2005-03-31 2005-07-28 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Ophthalmische Zusammensetzung
EP1916002B1 (en) * 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
BRPI0708891A2 (pt) * 2006-03-13 2011-06-28 R Tech Ueno Ltd composição aquosa
US8466174B2 (en) * 2006-03-17 2013-06-18 Johnson & Johnson Vision Care, Inc. Methods for stabilizing oxidatively unstable compositions
JP2010508306A (ja) * 2006-10-31 2010-03-18 アルコン リサーチ, リミテッド 眼障害を治療するためのpai−1結合調節因子
WO2008096804A1 (ja) * 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. ラタノプロスト含有点眼剤
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
BRPI0819081A8 (pt) * 2007-10-08 2016-08-30 Fovea Pharmaceuticals Sa Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
CN101959500A (zh) * 2008-03-17 2011-01-26 爱尔康研究有限公司 包含硼酸类化合物-多元醇络合物的水性药物组合物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
CA2830896A1 (en) * 2011-04-12 2012-10-18 Yukihiko Mashima Aqueous ophthalmic composition
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
SG11201403013VA (en) 2011-12-07 2014-07-30 Allergan Inc Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
UA121399C2 (uk) 2014-11-25 2020-05-25 Аллерган, Інк. Стабілізовані композиції для офтальмологічного застосування, які містять омега-3-кислоти
WO2020061550A1 (en) * 2018-09-21 2020-03-26 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
BR112021020425A2 (pt) 2019-04-12 2021-12-14 Ecolab Usa Inc Composições de limpeza multiuso concentrada e pronta para uso, e, métodos para limpar uma superfície e de fabricação da composição de limpeza multiuso

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059058T3 (es) * 1990-05-22 1994-11-01 R Tech Ueno Ltd Combinacion sinergica para uso oftalmico.
IE920397A1 (en) * 1991-02-07 1992-08-12 Allergan Inc 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f¹derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
EP0708646A1 (en) * 1994-05-06 1996-05-01 Alcon Laboratories, Inc. Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
CA2280089A1 (en) 1998-09-24
ATE257385T1 (de) 2004-01-15
CZ325799A3 (cs) 2000-01-12
KR100555818B1 (ko) 2006-03-03
JP4920124B2 (ja) 2012-04-18
AU7035398A (en) 1998-10-12
NO994481L (no) 1999-09-16
EP0969846B1 (en) 2004-01-07
DK0969846T3 (da) 2004-04-13
NO327713B1 (no) 2009-09-14
AU738781B2 (en) 2001-09-27
EE9900410A (et) 2000-04-17
TW527187B (en) 2003-04-11
DK0969846T4 (da) 2010-12-20
JP2001515502A (ja) 2001-09-18
IL131041A0 (en) 2001-01-28
DE69820997T2 (de) 2004-12-09
CA2280089C (en) 2009-03-03
CN1249687A (zh) 2000-04-05
BR9808016A (pt) 2000-03-08
CN1236775C (zh) 2006-01-18
DE69820997T3 (de) 2011-10-06
CL2009001870A1 (es) 2010-01-22
NO994481D0 (no) 1999-09-16
CY2526B1 (en) 2006-02-08
RU2197970C2 (ru) 2003-02-10
ES2214706T3 (es) 2004-09-16
HK1026841A1 (en) 2000-12-29
NZ337322A (en) 2001-05-25
ZA982188B (en) 1998-09-17
CO4940427A1 (es) 2000-07-24
PL335168A1 (en) 2000-04-10
SI0969846T1 (en) 2004-06-30
AR002194A1 (es) 1998-01-07
SI0969846T2 (sl) 2010-12-31
EP0969846B2 (en) 2010-08-25
MY122237A (en) 2006-04-29
PT969846E (pt) 2004-05-31
DE69820997D1 (de) 2004-02-12
HUP0002194A2 (hu) 2000-12-28
HUP0002194A3 (en) 2012-08-28
BRPI9816218B1 (pt) 2016-04-12
CZ299833B6 (cs) 2008-12-10
WO1998041208A1 (en) 1998-09-24
KR20000076330A (ko) 2000-12-26
UA63938C2 (uk) 2004-02-16
EE04091B1 (et) 2003-08-15
PL197509B1 (pl) 2008-04-30
ES2214706T5 (es) 2011-02-02
EP0969846A1 (en) 2000-01-12
JP2010043110A (ja) 2010-02-25
HU228896B1 (en) 2013-06-28
AR011192A1 (es) 2000-08-02
ID22389A (id) 1999-10-07

Similar Documents

Publication Publication Date Title
PE61899A1 (es) Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico
RU2009116609A (ru) Система доставки с контролируемым высвобождением для назального применения нейротрансмиттеров
KR890000098A (ko) 세포 및 조직 수복제
HRP20170769T1 (hr) Postupak i pripravak za liječenje očne hipertenzije i glaukoma
ES2186802T3 (es) Microemulsiones destinadas a usarse como vehiculos para la alimentacion de compuestos activos.
LU90837I2 (fr) Sonovue-hexaflorure et ses d-riv-s pharmaceutiquement acceptables
CO5011119A1 (es) Jarabe antihistaminico estabilizado
ES8205855A1 (es) Un procedimiento para la preparacion y estabilizacion de una composicion blanqueante acuosa que contiene peroxido de hi-drogeno.
RU94046143A (ru) Фармацевтическая композиция для лечения глаукомы
ATE273033T1 (de) Stabilisierte ophthalmische wasserstoffperoxidlösung
AR240837A2 (es) Una composicion detergente liquida y no acuosa, apropiada para lavar ropa de trabajo pesado, exenta de fosfato como reforzadores
DK0572190T3 (da) Oftalmiske præparater indeholdende vitamin E eller en ester deraf som en aktiv ingrediens
RU2004129593A (ru) Офтальмическая композиция, содержащая аскомицин
KR900002789A (ko) 안과용 용액을 보존하는 방법 및 이를 위한 조성물
AR247804A1 (es) Composicion biocida sinergica y metodo para proteger con la misma composiciones industriales
KR960706472A (ko) 프로스타글란딘 유도체, 그의 염 및 그의 사용
NO179837C (no) Nye tetrazolderivater, preparater inneholdende disse derivater samt deres anvendelse
ES500581A0 (es) Un procedimiento para la preparacion de una composicion detergente blanqueadora, del tipo que genera peracidos organicos
ATE150764T1 (de) Alkylester von oxidiertem glutathion
ES2022448B3 (es) Composicion desinfectante para lentes de contacto blandas, que contienen una disolucion de peroxido de hidrogeno estabilizada.
ATE270869T1 (de) ZUSAMMENSETZUNG MIT KONTINUIERLICHER WÄSSERIGER PHASE, DIE L-2-OXOTHIAZOLIDIN- 4-CARBONSÄURE ENTHÄLTß.
ES2163528T3 (es) Una solucion acuosa para infusion, estable al almacenamiento, que contiene un inhibidor de trombina.
SE8705064L (sv) Emulsion foer parenteral administrering
CO5601034A2 (es) Metodos para conservar soluciones oftalmicas y soluciones oftalmicas conservadas
AR245889A1 (es) Soluciones acuosas autoconservables para la limpieza y conservacion de las lentes de contacto blandas.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed